<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="372515">
  <stage>Registered</stage>
  <submitdate>8/03/2017</submitdate>
  <approvaldate>19/10/2017</approvaldate>
  <actrnumber>ACTRN12617001474347</actrnumber>
  <trial_identification>
    <studytitle>Pancreatic cancer: Understanding Routine Practice and Lifting End Results (PURPLE). A Prospective Pancreatic Cancer Clinical Registry </studytitle>
    <scientifictitle>Pancreatic cancer: Understanding Routine Practice and Lifting End Results (PURPLE). A Prospective Pancreatic Cancer Clinical Registry </scientifictitle>
    <utrn>U1111-1193-9819</utrn>
    <trialacronym>PURPLE Registry</trialacronym>
    <secondaryid>Nil Known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pancreatic Cancer </healthcondition>
    <healthcondition>Newly diagnosed Pancreatic Cancer</healthcondition>
    <healthcondition>Metastatic Pancreatic Cancer </healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Pancreatic</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The following end-points will be evaluated in this study: Time to progression from primary diagnosis (TTP). Progression-free survival (PFS). Overall survival (OS). This project is a multi-centre, prospective cohort study that will aim to enrol 800 patients at participating sites. It involves collection of data into the PURPLE registry, linkage and analysis of data via a WEHI developed database. Comprehensive clinicopathological data will be collected, start and stop dates for all systemic therapies will be captured as well as treatment response data for each therapy used, the reason for any change in treatment, and the date of disease progression. Data related to any resection of primary and or metastatic disease will be collected.
</interventions>
    <comparator>No control group</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Diagnosis / Prognosis</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Time to progression from primary diagnosis (TTP) will be assessed by treating doctor for up to 3 years at clinician's discretion using MRI scan,  CT scan or PET scan or PET-CT scan. 
</outcome>
      <timepoint>Assessed once per year for three years from enrolment. will be assessed by treating doctor for up to 3 years at clinician's discretion using MRI scan,  CT scan or PET scan or PET-CT scan. </timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Progression-free survival (PFS)will be assessed by treating doctor for up to 3 years at clinician's discretion using MRI scan,  CT scan or PET scan or PET-CT scan. </outcome>
      <timepoint>Once at the starts pf the study and at various timepoints for up to 3 years at clinician's discretion ,  will be assessed by MRI scan,  CT scan or PET scan or PET-CT scan. </timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Overall survival (OS will be assessed by will be assessed by treating doctor for up to 3 years at clinician's discretion using MRI scan,  CT scan or PET scan or PET-CT scan. </outcome>
      <timepoint>At the start of the study and during regular clinic visits at the hospital will be assessed by MRI scan,  CT scan or PET scan or PET-CT scan. </timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the impact of age, on clinicians treatment recommendations looking at patient medical records. </outcome>
      <timepoint>Assessed once per year for three years from enrolment. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the impact of co morbidity,   on clinicians treatment recommendations looking at patient medical records. </outcome>
      <timepoint>Assessed once per year for three years from enrolment. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To identify factors influencing the choice of FOLFOXIRI vs. Abraxane/ Gemcitabine in the first line setting by reviewing patient medical records. </outcome>
      <timepoint>Assessed once per year for three years from enrolment. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To obtain data on the most common chemotherapy regimens prescribed in the first-line setting by reviewing patient medical records</outcome>
      <timepoint>Assessed once per year for three years from enrolment. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To analyze the range of second-line chemotherapy choices for patients by looking at Medical records. .</outcome>
      <timepoint>Assessed once per year for three years from enrolment. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the rate at which adverse events that could be attributed to the treatment regimen occur in routine clinical practice by reviewing medical records</outcome>
      <timepoint>Assessed once per year for three years from enrolment. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome> To estimate the progression free survival  first. and second-line advanced unresectable or metastatic pancreatic cancer patients. By reviewing medical records. </outcome>
      <timepoint>Assessed once per year for three years from enrolment. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the number of patients that receive any treatment and for patients that are not treated the reasons that chemotherapy was not given by reviewing medical records.</outcome>
      <timepoint>Assessed once per year for three years from enrolment. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the range of chemotherapy choices (single or multiple options) given to patients by reviewing patient medical records</outcome>
      <timepoint>Assessed once per year for three years from enrolment. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the duration of treatment in the first and second line setting by reviewing patient medical records. </outcome>
      <timepoint>Assessed once per year for three years from enrolment. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome> To determine the number of patients undergoing potentially curative resection of distant metastases or alternative interventions by reviewing patient medical records</outcome>
      <timepoint>Assessed once per year for three years from enrolment. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>looking at overall survival of first and second-line advanced unresectable or metastatic pancreatic cancer patients. </outcome>
      <timepoint>Assessed once per year for three years from enrolment. </timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with newly diagnosed pancreatic cancer, with or without metastatic disease
b) Histologically or cytologically confirmed diagnosis of pancreatic cancer
c) Patients aged 18 years or above with any ECOG performance status with pancreatic cancer
d) Patients who are yet to receive treatment</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients that do not have a new diagnosis of pancreatic cancer. . </exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods>It is anticipated that a sample size of 800 is sufficient to achieve the aim of this study, and to achieve preliminary insights into variation in practice and outcomes across sites. In order to compare clinical outcomes across different subgroups, Kaplan-Meier survival curves will be defined from survival data and constructed using SAS (registered trademark) software. The stratified log rank test will be used to compare survival curves between different groups of participants. P-values of 0.05 will be considered significant. Due to the non-randomised nature of such comparisons propensity score techniques will be used to balance comparison groups according to baseline factors.</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>True</patientregistry>
    <followup>3</followup>
    <followuptype>Years</followuptype>
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate />
    <actualstartdate>15/02/2017</actualstartdate>
    <anticipatedenddate>31/07/2020</anticipatedenddate>
    <actualenddate />
    <samplesize>800</samplesize>
    <actualsamplesize />
    <currentsamplesize>40</currentsamplesize>
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>31/07/2023</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate>ACT,NSW,QLD,SA,TAS,WA,VIC</recruitmentstate>
    <hospital>Royal Melbourne Hospital - City campus - Parkville</hospital>
    <hospital>Western Hospital - Footscray - Footscray</hospital>
    <hospital>Peter MacCallum Cancer Centre - Melbourne</hospital>
    <hospital>Box Hill Hospital - Box Hill</hospital>
    <hospital>Cabrini Hospital - Malvern - Malvern</hospital>
    <hospital>Epworth Richmond - Richmond</hospital>
    <hospital>Monash Medical Centre - Clayton campus - Clayton</hospital>
    <hospital>Monash Medical Centre - Moorabbin campus - East Bentleigh</hospital>
    <hospital>St Vincent's Hospital (Melbourne) Ltd - Fitzroy</hospital>
    <hospital>Austin Health - Austin Hospital - Heidelberg</hospital>
    <hospital>The Alfred - Prahran </hospital>
    <hospital>Ballarat Health Services (Base Hospital) - Ballarat Central</hospital>
    <hospital>Goulburn Base Hospital - Goulburn</hospital>
    <hospital>The Northern Hospital - Epping</hospital>
    <hospital>Barwon Health - Geelong Hospital campus - Geelong</hospital>
    <hospital>Royal Brisbane &amp; Womens Hospital - Herston</hospital>
    <hospital>Gold Coast University Hospital - Southport</hospital>
    <hospital>The Canberra Hospital - Garran</hospital>
    <hospital>The Queen Elizabeth Hospital - Woodville</hospital>
    <hospital>Flinders Medical Centre - Bedford Park</hospital>
    <hospital>Prince of Wales Hospital - Randwick</hospital>
    <hospital>Liverpool Hospital - Liverpool</hospital>
    <hospital>Campbelltown Hospital - Campbelltown</hospital>
    <hospital>Southern Highlands Private Hospital - Bowral</hospital>
    <hospital>Westmead Hospital - Westmead</hospital>
    <hospital>Calvary Mater Newcastle - Waratah</hospital>
    <hospital>John Hunter Hospital - New Lambton</hospital>
    <hospital>The Chris Oâ€™Brien Lifehouse - Camperdown</hospital>
    <hospital>St John of God Hospital, Subiaco - Subiaco</hospital>
    <hospital>Royal Hobart Hospital - Hobart</hospital>
    <hospital>Fiona Stanley Hospital - Murdoch</hospital>
    <hospital>Wellington Health Service - Wellington</hospital>
    <postcode>3000 - Melbourne</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode>3011 - Footscray</postcode>
    <postcode>3128 - Box Hill</postcode>
    <postcode>3144 - Malvern</postcode>
    <postcode>3121 - Richmond</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode>3165 - East Bentleigh</postcode>
    <postcode>3065 - Fitzroy</postcode>
    <postcode>3084 - Heidelberg</postcode>
    <postcode>3004 - Prahran </postcode>
    <postcode>3350 - Ballarat Central</postcode>
    <postcode>2580 - Goulburn</postcode>
    <postcode>3076 - Epping</postcode>
    <postcode>3220 - Geelong</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>4215 - Southport</postcode>
    <postcode>2605 - Garran</postcode>
    <postcode>5011 - Woodville</postcode>
    <postcode>5042 - Bedford Park</postcode>
    <postcode>2031 - Randwick</postcode>
    <postcode>2170 - Liverpool</postcode>
    <postcode>2560 - Campbelltown</postcode>
    <postcode>2576 - Bowral</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>2298 - Waratah</postcode>
    <postcode>2305 - New Lambton</postcode>
    <postcode>2050 - Camperdown</postcode>
    <postcode>6008 - Subiaco</postcode>
    <postcode>7000 - Hobart</postcode>
    <postcode>6150 - Murdoch</postcode>
    <postcode>2820 - Wellington</postcode>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>hong kong </state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>Walter &amp; Eliza Hall Institute </primarysponsorname>
    <primarysponsoraddress> 1G Royal Parade
Parkville 3050 Victoria Australia </primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>Hemstritch Philanthropic fund </fundingname>
      <fundingaddress>Walter and Eliza Hall Institute 
 1G Royal Parade
Parkville 3050 Victoria Australia 
</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This project is non-interventional registry of the treatment and outcomes of patients with pancreatic cancer managed at hospitals enrolled to participate in Australia.

Who is it for?
You may be eligible to join this study if you are aged 18 years or above and have been newly diagnosed with pancreatic cancer (with or without metastatic disease) , with any ECOG performance status and are yet to receive treatment.

Study details
This registry will capture data on presentation and the disease course of pancreatic cancer, surgical interventions for primary and metastatic disease, prescription of systemic therapies, and information regarding multi-disciplinary management and outcomes of this disease in the routine clinical practice setting. This project will collect clinical data using the already established data collection and analysis resources built up over the last 15 years in the Systems Biology &amp; Personalised Medicine Division of the Walter &amp; Eliza Hall Institute of medical research (WEHI). This protocol aims to enrol at least 800 eligible patients over 10 years.
Findings from analyses that occur as part of this project are anticipated to improve our understanding of the presentation, clinical course and management of pancreatic cancer in Australia and other participating countries.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>MELBOURNE HEALTH HUMAN RESEARCH ETHICS COMMITTEE</ethicname>
      <ethicaddress>Office for Research
The Royal Melbourne Hospital
Level 2 South West
300 Grattan Street
Parkville VIC 3050 Victoria Australia </ethicaddress>
      <ethicapprovaldate>30/08/2016</ethicapprovaldate>
      <hrec>2016.200</hrec>
      <ethicsubmitdate>27/07/2016</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Peter Gibbs </name>
      <address>The Walter and Eliza Hall Institute of Medical Research
1G Royal Parade, Parkville VIC 3052 Australia</address>
      <phone>+61 3 93424269</phone>
      <fax>+61 3 93452317</fax>
      <email>Peter.Gibbs@mh.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Belinda Lee </name>
      <address>The Walter and Eliza Hall Institute of Medical Research
1G Royal Parade, Parkville VIC 3052 Australia</address>
      <phone>+61 3 9845 2853</phone>
      <fax>+61 3 93452317</fax>
      <email>Belinda.Lee@mh.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Belinda Lee </name>
      <address>The Walter and Eliza Hall Institute of Medical Research
1G Royal Parade, Parkville VIC 3052 Australia</address>
      <phone>+61 3 9845 2853</phone>
      <fax>+61 3 93452317</fax>
      <email>Belinda.Lee@mh.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Maria </name>
      <address>The Walter and Eliza Hall Institute of Medical Research
1G Royal Parade, Parkville VIC 3052 Australia</address>
      <phone>+613 9845 2896</phone>
      <fax>+61 3 93452317</fax>
      <email>Maria.Edmonds@mh.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>